Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIRANUS: Atezolizumab Plus Tiraglolumab With Chemoradiotherapy in Localized Squamous Cell Carcinoma of the Anal Canal
NCT05661188Phase 2Completed
- Sponsor
- GEMCAD
- Start
- Feb 2023
- Primary completion
- Sep 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab and tiragolumab in anal canal squamous cell carcinoma (SCCA), sponsored by GEMCAD. Primary endpoint: Clinical complete response at 26 weeks. Started Feb 2023; status: completed.
02
Drugs
atezolizumabtiragolumab
03
Conditions
anal canal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on NCT05661188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05661188.